Potentsial'nye vozmozhnosti metformina v profilaktike i lechenii onkologicheskikh zabolevaniy u bol'nykh sakharnym diabetom 2 tipa

Abstract

Diabetes mellitus is associated with increased risk of several types of cancer, and also with increased cancer mortality. Chronic hyperinsulinemia plays the main pathogenetic role in this association, which is mediated by a number of molecular mechanisms, described in this issue. Drugs that increase insulin sensitivity and reduce hyperinsulinemia (metformin in the first place) display anticancer effect. Aside from the anticancer effect, mediated by reduction of insulin resistance, metformin may directly suppress cancer cells growth and proliferation via stimulation of AMP kinase (AMPK). Antiproliferative action of metformin in breast and ovarian cancer is confirmed in a number of experimental and clinical trials. Its found out that therapeutic effect of metformin in treatment of breast cancer depends on the presence/absence of some molecular features of the tumor (for example, increased expression of HER2 and/or activation of p70S6K1). In order to specify mechanisms of action and effects of metformin in oncological practice several trials are being conducted or planned, most of all, in all subtypes of breast cancer. Confirmation of the anticancer effectiveness of metformin will promote an expansion of its use in clinical practice and in clinical oncology, particularly.

Diabetes, obesity and cancer: risk and anti-risk factors

“…Тот факт, что характер лечения СД может сказываться на частоте онкологической заболеваемости и, возможно, ее структуре, начал активно привлекать внимание с начала 2000 годов, хотя отдельные сведения такого рода появлялись и ранее. С учетом ограниченности места для изложения и ранее публиковавшихся в отечественной печати обобщений, главным образом по метформину [51,52,53,54], представляется целесообразным дать сжатую информацию о тенденциях, складывающихся в обсуждаемом отношении применительно к основным антидиабетическим средствам.…”